영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - pergolide mesilate - oral tablet - 1mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - pergolide mesilate - oral tablet - 1mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - pergolide mesilate - oral tablet - 1mg

미국 - 영어 - NLM (National Library of Medicine)

dr. reddy's laboratories inc. - azacitidine (unii: m801h13nru) (azacitidine - unii:m801h13nru) - azacitidine 100 mg - azacitidine for injection is indicated for treatment of adult patients with the following french-american- british (fab) myelodysplastic syndrome subtypes: refractory anemia (ra) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (raeb), refractory anemia with excess blasts in transformation (raeb-t), and chronic myelomonocytic leukemia (cmmol). pediatric use information is approved for celgene corporation's vidaza (azacitidine for injection). however, due to celgene corporation's marketing exclusivity rights, this drug product is not labeled with that information. azacitidine for injection is contraindicated in patients with advanced malignant hepatic tumors [see warnings and precautions (5.3)]. azacitidine for injection is contraindicated in patients with a known hypersensitivity to azacitidine or mannitol. risk summary based on its mechanism of action and findings in animals, azacitidine for injec

미국 - 영어 - NLM (National Library of Medicine)

dr. reddy's laboratories inc. - azacitidine (unii: m801h13nru) (azacitidine - unii:m801h13nru) - azacitidine for injection is indicated for treatment of adult patients with the following french-american- british (fab) myelodysplastic syndrome subtypes: refractory anemia (ra) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (raeb), refractory anemia with excess blasts in transformation (raeb-t), and chronic myelomonocytic leukemia (cmmol). pediatric use information is approved for celgene corporation's vidaza (azacitidine for injection). however, due to celgene corporation's marketing exclusivity rights, this drug product is not labeled with that information. azacitidine for injection is contraindicated in patients with advanced malignant hepatic tumors [see warnings and precautions (5.3)]. azacitidine for injection is contraindicated in patients with a known hypersensitivity to azacitidine or mannitol. risk summary based on its mechanism of action and findings in animals, azacitidine for injec

미국 - 영어 - NLM (National Library of Medicine)

trigen laboratories, llc - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg